tbuckley/cabot-search huggingface dataset:
Self‐Powered Implantable Medical Devices: Photovoltaic Energy Harvesting Review
Authors: Jinwei Zhao, Rami Ghannam, Kaung Oo Htet, Yuchi Liu, Man‐kay Law, Vellaisamy A. L. Roy, Bruno Michel, Muhammad Ali Imran, Hadi Heidari
Journal: Advanced Healthcare Materials (2020)

Implantable technologies are becoming more widespread for biomedical applications that include physical identification, health diagnosis, monitoring, recording, and treatment of human physiological traits. However, energy harvesting and power generation beneath the human tissue are still a major challenge. In this regard, self-powered implantable devices that scavenge energy from the human body are attractive for long-term monitoring of human physiological traits. Thanks to advancements in material science and nanotechnology, energy harvesting techniques that rely on piezoelectricity, thermoelectricity, biofuel, and radio frequency power transfer are emerging. However, all these techniques suffer from limitations that include low power output, bulky size, or low efficiency. Photovoltaic (PV) energy conversion is one of the most promising candidates for implantable applications due to their higher-power conversion efficiencies and small footprint. Herein, the latest implantable energy harvesting technologies are surveyed. A comparison between the different state-of-the-art power harvesting methods is also provided. Finally, recommendations are provided regarding the feasibility of PV cells as an in vivo energy harvester, with an emphasis on skin penetration, fabrication, encapsulation, durability, biocompatibility, and power management.
LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
Authors: N. Boku, M.H. Ryu, D-Y. Oh, S.C. Oh, H.C. Chung, K-W. Lee, T. Omori, K. Shitara, S. Sakuramoto, I.J. Chung, K. Yamaguchi, K. Kato, S.J. Sym, S. Kadowaki, K. Tsuji, J-S. Chen, L-Y. Bai, L-T. Chen, Y-K. Kang
Journal: Annals of Oncology (2020)
Hierarchical Representation for Chromatic Processing across Macaque V1, V2, and V4
Authors: Ye Liu, Ming Li, Xian Zhang, Yiliang Lu, Hongliang Gong, Jiapeng Yin, Zheyuan Chen, Liling Qian, Yupeng Yang, Ian Max Andolina, Stewart Shipp, Niall Mcloughlin, Shiming Tang, Wei Wang
Journal: Neuron (2020)
610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Authors: J.S. de Bono, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K.N. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, G. Roubaud, M. Ozguroglu, J. Kang, J. Burgents, C. Gresty, C. Corcoran, C.A. Adelman, M. Hussain
Journal: Annals of Oncology (2020)
1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Authors: G.J. Riely, J.W. Neal, D.R. Camidge, A. Spira, Z. Piotrowska, L. Horn, D.B. Costa, A. Tsao, J. Patel, S. Gadgeel, L. Bazhenova, V.W. Zhu, H. West, T. Mekhail, R. Gentzler, D. Nguyen, V. Bunn, S. Jin, Z. Feng, P.A. Jänne
Journal: Annals of Oncology (2020)
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL
Authors: Huiying Han, Gao Fan, Sha Song, Yunxin Jiang, Chen'ao Qian, Weimin Zhang, Qi Su, Xiaofeng Xue, Wenzhuo Zhuang, Bingzong Li
Journal: Blood (2020)
1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma
Authors: A.A.N. Rose, D. Kelly, D. Hogg, M.O. Butler, S. Saibil, H. Krema, I. King, Z. Saeed Kamil, D. Ghazarian, D.P. Arteaga Ceballos, D.V. Araujo, T. Muniz, J. Waldron, N. Laperriere, A. Spreafico
Journal: Annals of Oncology (2020)
975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma
Authors: X. Le, I. Gluck, C. Maurice-Dror, A. Panwar, K. Gold, J. Berlin, T. Dai, J. Grewal, M. Nagasaka, A. Rosenberg, M. Haigentz, C. Le Tourneau, I. Moreno, M. McDevitt, M. Patel, D. Da Costa, S. Lambert, Y. Li, M. Blaney, M. Gillison
Journal: Annals of Oncology (2020)
884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
Authors: N. Colombo, Y. Antill, M.P. Barretina Ginesta, K. Harano, E. Hudson, F. Marmé, C. Marth, M. Rabaglio, A.A. Secord, R. Fossati, A. Roberto, F. Tettamanzi, E. Biagioli
Journal: Annals of Oncology (2020)
527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
Authors: V. Moreno, I. Braña, J.M. Sepulveda Sanchez, M. Vieito, T. Hernández-Guerrero, B. Doger, O. Saavedra, C. Carlo-Stella, J-M. Michot, A. Italiano, G. Musuraca, R. Sarmiento, B. Amoroso, S. Mora, T. Sánchez-Pérez, I. Aronchik, E. Filvaroff, B. Hanna, Z. Nikolova, A. Pinto
Journal: Annals of Oncology (2020)
1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
Authors: K.J. O'Byrne, K.H. Lee, S-W. Kim, K. Park, M. Nishio, H. Sakai, Y. Ohe, T. Fukuhara, J-H. Kang, H. Daga, C-J. Yu, K. Hotta, H. Tanaka, M. Takeda, T. Yokoyama, F.E. Nathan, J-S. Lee
Journal: Annals of Oncology (2020)
1002P Usefulness of hand-foot skin reaction as a prognostic marker in patients with hepatocellular carcinoma treated with sorafenib: Close cooperation between pharmacists and oncologist changes prognosis
Authors: T. Kamoshida, M. Ochi, T. Ikegami, M. Araki, Y. Yamaguchi, Y. Hamano, H. Ohkawara, A. Ohkawara, N. Kakinoki, S. Hirai, A. Yanaka
Journal: Annals of Oncology (2020)
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
Authors: Jong Hwa Choi, Won Sohn, Yong Kyun Cho
Journal: Clinical and Molecular Hepatology (2020)

Nonalcoholic fatty liver disease (NAFLD) is defined by fat accumulation in liver that is not caused by excessive alcohol consumption. Safe limits of alcohol consumption in NAFLD are usually defined as alcohol consumption of less than 210 g per week for men and 140 g per week for women (30 g/day in men, 20 g/day in women) and alcohol consumption below safe limits is generally regarded as moderate alcohol consumption. Many studies have investigated the effects of moderate alcohol consumption on NAFLD patients. Some studies showed that moderate alcohol consumption prevented the progression of fibrosis in the liver, whereas other reports showed worsening of fibrosis in the liver based on serologic, radiologic and liver biopsy findings compared with effects on total abstainers. NAFLD is also thought to be a hepatic manifestation of metabolic syndrome, and when combined with excessive alcohol consumption results in the development of components of metabolic syndrome and systemic harmful effects. The effects of moderate alcohol consumption on NAFLD have yet to be established.
356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
Authors: H.S. Rugo, A. Llombart Cussac, F. André, M. Robson, S. Saji, N. Harbeck, P. Schmid, D.W. Cescon, J. Seok Ahn, R. Nanda, L. Fan, J. Mejia, V. Karantza, A. Bardia
Journal: Annals of Oncology (2020)
1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240
Authors: A. Vogel, P. Merle, C. Verslype, R.S. Finn, A.X. Zhu, A-L. Cheng, S.L. Chan, T. Yau, B-Y. Ryoo, Z. Wei, U. Malhotra, A.B. Siegel, M. Kudo
Journal: Annals of Oncology (2020)
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Authors: J.W. Goldman, M.C. Garassino, Y. Chen, N. Reinmuth, K. Hotta, A. Poltoratskiy, D. Trukhin, M.J. Hochmair, M. Özgüroğlu, J.H. Ji, G. Statsenko, O. Voitko, N.V. Conev, I. Bondarenko, S. Spencer, M. Xie, S. Jones, A. Franks, Y. Shrestha, L. Paz-Ares
Journal: Annals of Oncology (2020)
261P A novel dose-dense alternating regimen of Docetaxel-Cyclophosphamide with Epirubicin-Cisplatin (ddDCEP) as neoadjuvant chemotherapy (NACT) for high-risk triple-negative breast cancer
Authors: J.T. Georgy, A. Singh, A. Oommen, A. Joel, M.T. Manipadam, D.T. Abraham, M.J. Paul, S. Backianathan, R.T. Chacko
Journal: Annals of Oncology (2020)
Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals
Authors: Ronald A. Seaton, Cheryl L. Gibbons, Lesley Cooper, William Malcolm, Rachel McKinney, Stephanie Dundas, David Griffith, Danielle Jeffreys, Kayleigh Hamilton, Brian Choo-Kang, Suzanne Brittain, Debbie Guthrie, Jacqueline Sneddon
Journal: Journal of Infection (2020)

Concern regarding bacterial co-infection complicating SARS-CoV-2 has created a challenge for antimicrobial stewardship. Following introduction of national antibiotic recommendations for suspected bacterial respiratory tract infection complicating COVID-19, a point prevalence survey of prescribing was conducted across acute hospitals in Scotland.
Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis
Authors: Jean-Jacques Kiladjian, Pierre-Edouard Debureaux, Aurélie Plessier, Juliette Soret-Dulphy, Dominique Valla, Bruno Cassinat, Pierre-Emmanuel Rautou
Journal: Journal of Hepatology (2020)
438P Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Authors: S. Kasper, R.D. Hofheinz, S. Stintzing, T.O. Götze, M. Sinn, T. Dechow, T.J. Ettrich, V. Keitel, U. Graeven, L. Fischer von Weikersthal, A. Kolov, T. Edelmann, A. Stein, T. Trarbach, S. Junge, C. Pauligk, I. Virchow, J. Siveke, S-E. Al-Batran, M. Schuler
Journal: Annals of Oncology (2020)
1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients
Authors: M. Cabeza, V. Gambardella, L. Alarcón, G. Herrera, Z. Garzón-Lloría, C. Martínez-Ciarpaglini, J.A. Carbonell-Asíns, R. Villagrasa, P. Navarro, M. Gil, P. Richart, F. López, M.D.C. Fernández, M. Huerta, A. Cervantes, J. Castillo, T. Fleitas
Journal: Annals of Oncology (2020)
821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
Authors: A. Dean, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, N. Colombo, J. Weberpals, A.R. Clamp, G. Scambia, A. Leary, R.W. Holloway, M. Amenedo Gancedo, P.C. Fong, J.C. Goh, D.M. O'Malley, T. Cameron, L. Maloney, S. Goble, R.L. Coleman, J.A. Ledermann
Journal: Annals of Oncology (2020)
451P Novel somatic genetic variants as predictors of resistance to EGFR-targeted therapies in metastatic colorectal cancer patients
Authors: P. Riera, B. Rodríguez-Santiago, A. Lasa, L. González-Quereda, B. Martín, J. Salazar, A. Sebio Garcia, A.C. Virgili Manrique, J. Surrallés, D. Páez
Journal: Annals of Oncology (2020)
757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status
Authors: A. Rezazadeh, Y. Loriot, D. Papantoniou, A.O. Siefker-Radtke, A. Necchi, V. Naini, A. Santiago-Walker, A. Galluzzi, M. Monga, E.F. Burgess
Journal: Annals of Oncology (2020)
1395P Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC?
Authors: J.H. Yeo, S.H. Park, H.A. Jung, J-M. Sun, S.H. Lee, J.S. Ahn, K. Park, M-J. Ahn
Journal: Annals of Oncology (2020)
Update: Characteristics of Health Care Personnel with COVID-19 — United States, February 12–July 16, 2020
Authors: Michelle M. Hughes, Matthew R. Groenewold, Sarah E. Lessem, Kerui Xu, Emily N. Ussery, Ryan E. Wiegand, Xiaoting Qin, Tuyen Do, Deepam Thomas, Stella Tsai, Alexander Davidson, Julia Latash, Seth Eckel, Jim Collins, Mojisola Ojo, Lisa McHugh, Wenhui Li, Judy Chen, Jonathan Chan, Jonathan M. Wortham, Sarah Reagan-Steiner, James T. Lee, Sujan C. Reddy, David T. Kuhar, Sherry L. Burrer, Matthew J. Stuckey
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

As of September 21, 2020, the coronavirus disease 2019 (COVID-19) pandemic had resulted in 6,786,352 cases and 199,024 deaths in the United States.*Health care personnel (HCP) are essential workers at risk for exposure to patients or infectious materials (1).The impact of COVID-19 on U.S. HCP was first described using national case surveillance data in April 2020 (2).Since then, the number of reported HCP with COVID-19 has increased tenfold.This update describes demographic characteristics, underlying medical conditions, hospitalizations, and intensive care unit (ICU) admissions, stratified by vital status, among 100,570 HCP with COVID-19 reported to CDC during February 12-July 16, 2020.HCP occupation type and job setting are newly reported.HCP status was available for 571,708 (22%) of 2,633,585 cases reported to CDC.Most HCP with COVID-19 were female (79%), aged 16-44 years (57%), not hospitalized (92%), and lacked all 10 underlying medical conditions specified on the case report form † (56%).Of HCP with COVID-19, 641 died.Compared with nonfatal COVID-19 HCP cases, a higher percentage of fatal cases occurred in males (38% versus 22%), persons aged ≥65 years (44% versus 4%), non-Hispanic Asians (Asians) (20% versus 9%), non-Hispanic Blacks (Blacks) (32% versus 25%), and persons with any of the 10 underlying medical conditions specified on the case report form (92% versus 41%).From a subset of jurisdictions reporting occupation type or job setting for HCP with COVID-19, nurses were the most frequently identified single occupation type (30%), and nursing and residential care facilities were the most common job setting (67%).Ensuring access to personal protective equipment (PPE) and training, and practices such as universal use of face masks at work, wearing masks in the community, * https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html;https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html;https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html.† Underlying medical condition status was classified as "known" if any of these 10 conditions, specified on the standard case report form, were reported as present or absent: diabetes mellitus; cardiovascular disease (includes hypertension); severe obesity (body mass index ≥40 kg/m 2 ); chronic renal disease; chronic liver disease; chronic lung disease; immunosuppressive condition; autoimmune condition; neurologic condition (including neurodevelopmental, intellectual, physical, visual, or health impairment); and psychologic/psychiatric condition.
1166MO Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas
Authors: C. Lamy, H. Tissot, M. Faron, E. Baudin, S. Leboulleux, A. Paci, J. Hadoux, S. Broutin
Journal: Annals of Oncology (2020)
1050P Does immunotherapy impact the outcomes of future anti-tumour therapies?
Authors: M. Tiako Meyo, R. Sun, S. Champiat, J-M. Michot, C. Baldini, A. Gazzah, R. Bahleda, P. Martin-Romano, A. Hollebecque, A. Varga, A. Marabelle, C. Massard
Journal: Annals of Oncology (2020)
Trends in worldwide asthma prevalence
Authors: M. Innes Asher, Luis García-Marcos, Neil E. Pearce, David P. Strachan
Journal: European Respiratory Journal (2020)

This review of trends in worldwide asthma prevalence starts with defining how asthma prevalence is measured in populations and how it is analysed. Four population studies of asthma across at least two regions are described: European Community Respiratory Health Survey (ECRHS), the International Study of Wheezing in Infants (EISL), the International Study of Asthma and Allergies in Childhood (ISAAC) and the World Health Survey (WHS). Two of these (ISAAC and WHS) covered all the regions of the world; each using its own standardised questionnaire-based methodology with cross-sectional study design, suitable for large populations. EISL (2005 and 2012) and ISAAC (1996–1997 and 2002–2003) have undertaken a second cross-sectional population survey from which trends are available: EISL in three centres in two countries; ISAAC 106 centres in 56 countries (13–14 year olds) and 66 centres in 37 countries (6–7 year olds). Key results from these studies are presented. Unfortunately, there is no new worldwide data outside of EISL since 2003. Global Burden of Disease estimates of asthma prevalence have varied greatly. Recent reliable worldwide data on asthma prevalence and trends is needed; the Global Asthma Network Phase I will provide this in 2021.
Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism Is Associated with a Significant Decrease in Incidence of Bleeding Compared to Vitamin K Antagonists and Low-Molecular-Weight Heparins
Authors: Ameet Patel, Hants Williams, Maria R. Baer, Ann Butler Zimrin, Jennie Y Law
Journal: Blood (2017)
Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population‐Based Retrospective Cohort Study From the United Kingdom
Authors: Ruchika Goel, Joht Singh Chandan, Rasiah Thayakaran, Nicola J. Adderley, Krishnarajah Nirantharakumar, Lorraine Harper
Journal: Arthritis & Rheumatology (2020)

Cardiovascular disease (CVD) is a major complication and cause of mortality in Takayasu arteritis (TAK), but population-based controlled studies from the UK are lacking. We undertook the present study to investigate the frequency of morbidity and mortality related to CVD, as well as to cerebrovascular and kidney disease, among patients with TAK in the UK.Yearly cohort and cross-sectional studies were performed from 2000 to 2017 to estimate annual incidence and prevalence, respectively, of TAK. Using a UK primary care database (IQVIA Medical Research Data), an open retrospective matched cohort study was conducted to estimate risk of hypertension, diabetes, cardiovascular morbidity, chronic kidney disease (CKD), and all-cause mortality in TAK. Risk (adjusted hazard ratio [HR]) of the assessed comorbidities among patients with TAK compared to age- and sex-matched controls was estimated. Changes in medication prescription over time were examined in both groups.One hundred forty-two patients with TAK (median age 53.4 years [interquartile range 33.8-70.7]) and 1,371 matched controls were included. The annual incidence and prevalence of TAK were 0.8 per million and 7.5 per million respectively. All-cause mortality was increased in TAK (adjusted HR 1.88 [95% confidence interval 1.29-2.76]). Patients with TAK had an increased risk of developing ischemic heart disease, stroke/transient ischemic attack, combined CVD, and peripheral vascular disease compared to controls, but no increase in risk of hypertension, CKD, heart failure, or diabetes. Only ~50% of patients with TAK requiring secondary CVD prevention were prescribed statins or antiplatelet agents within 1 year after study entry.Cardiovascular morbidity was increased among patients with TAK receiving primary care services in the UK. Treatment with statins and antiplatelet agents in these patients was suboptimal.
28P Frequency and spectrum of founder and non-founder BRCA1/2 mutations in a large series of Russian breast cancer and ovarian cancer patients
Authors: T.N. Sokolova, A. Sokolenko, V. Ni, E. Preobrazhenskaya, A. Iyevleva, S. Aleksakhina, A. Bessonov, T. Gorodnova, E. Anisimova, E. Savonevich, P. Krivorotko, I. Berlev, E. Imyanitov
Journal: Annals of Oncology (2020)
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study
Authors: Katherine Samaras, Steve Makkar, John D. Crawford, Nicole A. Kochan, Wei Wen, Brian Draper, Julian N. Trollor, Henry Brodaty, Perminder S. Sachdev
Journal: Diabetes Care (2020)

OBJECTIVE Type 2 diabetes (diabetes) is characterized by accelerated cognitive decline and higher dementia risk. Controversy exists regarding the impact of metformin, which is associated with both increased and decreased dementia rates. The objective of this study was to determine the association of metformin use with incident dementia and cognitive decline over 6 years in participants with diabetes compared with those not receiving metformin and those without diabetes. RESEARCH DESIGN AND METHODS A prospective observational study was conducted of N = 1,037 community-dwelling older participants without dementia aged 70–90 years at baseline (the Sydney Memory and Ageing Study). Exclusion criteria were dementia, major neurological or psychiatric disease, or progressive malignancy. Neuropsychological testing measured cognitive function every 2 years; a battery of tests measured executive function, memory, attention/speed, language, and visuospatial function individually. These were used to determine the measure of global cognition. Incident dementia was ascertained by a multidisciplinary panel. Total brain, hippocampal, and parahippocampal volumes were measured by MRI at baseline and 2 years (n = 526). Data were analyzed by linear mixed modeling, including the covariates of age, sex, education, BMI, heart disease, hypertension, stroke, smoking, and apolipoprotein Eε4 carriage. RESULTS Of n = 1,037, 123 had diabetes; 67 received metformin (DM+MF) and were demographically similar to those who did not (DM-noMF) and participants without diabetes (no-DM). DM+MF had significantly slower global cognition and executive function decline compared with DM-noMF. Incident dementia was significantly higher in DM-noMF compared with DM+MF (odds ratio 5.29 [95% CI 1.17–23.88]; P = 0.05). CONCLUSIONS Older people with diabetes receiving metformin have slower cognitive decline and lower dementia risk. Large randomized studies in people with and without diabetes will determine whether these associations can be attributed to metformin.
1359P Clinical characteristics of advanced NSCLC patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations
Authors: S.N. Daher, R. Yacobi, I. Barshack, S. Tsabari, Y. Rotenberg, T. Kuznetsov, A. Lobachov, A. Zick, A. Saad, H. Gantz-Sorotsky, D. Urban, A. Onn, J. Bar
Journal: Annals of Oncology (2020)
1579P Burnout among oncology professionals in the Middle East and North Africa (MENA)
Authors: A.M. Abusanad, A. Bensalem, E. Shash, L.Y.I. Mula-Hussain, Z. Benbrahim, S. Khatib, N. Abdelhafiz, J. Ansari, H. Jradi, K. Alkattan, A.R. Jazieh
Journal: Annals of Oncology (2020)
238P Beneficial effects of exercise in oncology - MoviS: ‘Movement and Health Beyond Care’
Authors: R. Emili, V. Natalucci, C.F. Marini, F. Lucertini, L. Vallorani, G. Annibalini, M. De Santi, S. Donati Zeppa, D. Agostini, M. Gervasi, A. Panico, D. Sisti, M.B.L. Rocchi, S. Barocci, M. Flori, G. Brandi, V. Stocchi, V. Catalano, A. Villarini, E. Barbieri
Journal: Annals of Oncology (2020)